The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done in stem cell transplant recipients to see if taking the drug valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur 100 days or later after transplant.

• Phase: Phase 3

Details

• Lead Sponsor: Mayo Clinic
• Collaborators: City of Hope National Medical Center; Fred Hutchinson Cancer Research Center; Roche Pharma AG; University of Florida; University of Michigan
• Treatments: Ganciclovir; Valganciclovir

Criteria

Participants who are undergoing allogeneic peripheral blood stem cell, cord blood, or marrow transplantation that are 18 years of age or older, may be eligible to participate in this study.